Search Results
Jun 24, 2026, 05:45 ET Zafin lança AIOS, plataforma completa para orquestrar e governar trabalho com agentes de IA
uma plataforma de execução bancária baseada em IA para produtos, preços, ofertas, cobrança, fidelidade, relacionamento e regras de negócio; e a Zafin IO, uma plataforma de integração de dados, eventos, serviços, fluxos de trabalho e aplicações em ambientes corporativos regulados.Juntas, elas traduzem
More news about: Zafin Labs Americas
Jun 24, 2026, 04:55 ET Zafin lanza AIOS, una plataforma integral para coordinar y gestionar el trabajo agéntico
bancaria impulsada por IA para productos, precios, ofertas, facturación, fidelización, gestión de relaciones y lógica de acuerdos comerciales; y Zafin IO, la plataforma de integración encargada de conectar datos, eventos, servicios, flujos de trabajo y aplicaciones en entornos empresariales regulados.Juntos,
More news about: Zafin Labs Americas
Jun 24, 2026, 02:38 ET Movate and MelodyArc Announce Applied AI Partnership to Transform CX Operations with AI-Powered Workflow Orchestration
The partnership strengthens Movate's Applied AI platform, Mova iO, by incorporating MelodyArc's AI orchestration capabilities directly into agent workflows and customer service operations. Movate brings almost 30 years
More news about: Movate
Jun 23, 2026, 17:43 ET Zafin lance AIOS, une plateforme de bout en bout destinée à orchestrer et à piloter le travail agentique
produits, de la tarification, des offres, de la facturation, de la fidélisation, de la relation client et de la logique des transactions ; et Zafin IO, la plateforme d'intégration permettant de relier les données, les événements, les services, les flux de travail et les applications au sein d'environnements
More news about: Zafin
Jun 23, 2026, 17:37 ET Zafin lanza AIOS, una plataforma integral para orquestar y gestionar el trabajo de los agentes
plataforma de ejecución bancaria impulsada por IA para la lógica de productos, precios, ofertas, facturación, fidelización, relaciones y acuerdos; y Zafin IO, la plataforma de integración para conectar datos, eventos, servicios, flujos de trabajo y aplicaciones en entornos empresariales regulados.En
More news about: Zafin Labs Americas
Jun 23, 2026, 12:45 ET OPAQUE Extends the Agent Governance Toolkit with Verifiable Identity and First Ever Verifiably Governed and Secure MCP
https://github.com/agentrust-ioOPAQUE will also launch the agentrust-io Fellowship, a sponsored program created by Chief Platform Officer Imran Siddique that invites security engineers,
More news about: OPAQUE
Jun 23, 2026, 08:15 ET Zafin Launches AIOS, an End-to-End Platform to Orchestrate and Govern Agentic Work
Zafin Banking Platform, the AI-powered banking execution platform for product, pricing, offers, billing, loyalty, relationship and deal logic; and Zafin IO, the integration platform for connecting data, events, services, workflows and applications across regulated enterprise environments.Together,
More news about: Zafin Labs Americas
Jun 23, 2026, 08:15 ET Zafin Launches AIOS, an End-to-End Platform to Orchestrate and Govern Agentic Work
Zafin Banking Platform, the AI-powered banking execution platform for product, pricing, offers, billing, loyalty, relationship and deal logic; and Zafin IO, the integration platform for connecting data, events, services, workflows and applications across regulated enterprise environments.Together,
More news about: Zafin Labs Americas
Jun 23, 2026, 08:15 ET Zafin bringt AIOS auf den Markt, eine End-to-End-Plattform zur Koordination und Steuerung agentenbasierter Arbeitsabläufe
von Bankgeschäften in den Bereichen Produkt, Preisgestaltung, Angebote, Abrechnung, Kundenbindung, Kundenbeziehungen und Geschäftslogik; sowie Zafin IO, die Integrationsplattform zur Vernetzung von Daten, Ereignissen, Diensten, Workflows und Anwendungen in regulierten Unternehmensumgebungen.Zusammen
More news about: Zafin Labs Americas
Jun 23, 2026, 05:00 ET Leetx Introduces EcoMove Smart Electric Cylinder to Simplify Press‑Fit Station Integration
overshoot below 2%Storage for up to 32 process programs for rapid changeoverSupport for multiple industrial bus protocols and standard IO20× lower energy consumption and noise level of 75 dB vs. hydraulic alternativesAll core modules — mechanical structure, control
More news about: Leetx
Jun 22, 2026, 14:14 ET Phanes Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Spevatamig in Combination with Chemotherapy for the Frontline Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
/PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), today announced the completion of enrollment in its Phase 2 study of spevatamig in combination of standard of care chemotherapy for metastatic PDAC
More news about: Phanes Therapeutics, Inc.
Jun 18, 2026, 11:00 ET Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
overall survival (mOS) was 19.4 months, with a 12-month OS rate of 72.7% and a 24-month OS rate of 49.1%.Among the 31 post-IO patients evaluable for efficacy, cORR and DCR were 29.00% and 77.40%, respectively. Median PFS was 4.0 months and median DoR was 9.1 months. Median
More news about: Mabwell
Jun 18, 2026, 07:00 ET Hirevue AI Interviewer Sets New Enterprise Standard Grounded in Validated Hiring Science
interviews with every applicant 24/7, helping surface real job-specific capabilities beyond traditional screening questions. Responses can be scored against IO-validated rubrics built from thousands of outcome studies, giving recruiters an evaluated, ranked-for-review, and evidence-backed prioritization of candidates
More news about: Hirevue
Jun 17, 2026, 10:11 ET RS supports panel-centric MRO strategies that deliver savings without sacrificing quality
functional safety requirements to ensure reliable performance and standards compliance. Additionally, select models support fieldbus communications and IO-Link protocols that facilitate access to diagnostic data, reduce troubleshooting expenses, and improve system availability.
More news about: RS
Jun 17, 2026, 08:01 ET Nectin Therapeutics Reports Encouraging Phase 1 Results for NTX1088 in Combination with Keytruda® (pembrolizumab) at ASCO 2026
oncology (IO) therapies and antibody drug conjugates (ADCs). The company's differentiated therapies have the potential to set new standards for efficacy and patient response rates across various difficult-to-treat cancers. Nectin's technology addresses major escape mechanisms of current IO therapies
More news about: Nectin Therapeutics, LTD.
Jun 15, 2026, 02:52 ET Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
first-line TNBC is ongoing. The combination of AK138D1 and ivonescimab is poised to emerge as a highly differentiated "IO2.0 + ADC2.0" therapeutic strategy for advanced breast cancer.As IO+ADC combinations become a cornerstone of global oncology research, Akeso is strategically and efficiently building
More news about: Akeso, Inc.
Jun 11, 2026, 04:00 ET Climate Impact Partners secures a historic one million tonne carbon removals purchase from GreenTrees' Mississippi Alluvial Valley ARR Project
rigour of a CCP-approved methodology, the project uses proprietary Digital Measurement, Reporting, and Verification (dMRV) technologies powered by ACRE IO to deliver frequent, highly accurate carbon measurements. This supports continuous operational improvement - including replanting - while ensuring project
More news about: ACRE Investment Management; Climate Impact Partners (CIP)
Jun 11, 2026, 02:20 ET CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
Later-Line NSCLC Monotherapy (Pretreated with IO, Chemotherapy, ADCs, or Bispecifics)Overall ORR in the 30 mg/kg cohort: 24% (squamous 25%, non-squamous 23.1%, consistent benefit); DCR 60%;In second-line NSCLC (30 mg/kg, post IO + chemotherapy): ORR improved to 30.8%,
More news about: CStone Pharmaceuticals
Jun 09, 2026, 08:33 ET Byreal Launches Byreal Predict: An Onchain Prediction Market
www.byreal.ioFor updates, please follow Byreal's social media: https://x.com/byreal_ioFor media inquiries, please contact: [email protected]
More news about: Byreal
Jun 09, 2026, 08:20 ET Byreal Launches Byreal Predict: An Onchain Prediction Market
www.byreal.ioFor updates, please follow Byreal's social media: https://x.com/byreal_ioFor media inquiries, please contact: [email protected]
More news about: Byreal
Jun 08, 2026, 10:11 ET RS and Banner Engineering deliver plug-and-play Industry 4.0 sensors engineered for problem-solving
and evaluate ROI before scaling and achieve non-linear revenue growth without a proportional, linear spike in overhead.They also support IO-Link communication, which eliminates EMI/RFI and the cost of associated solutions, like shielded cable, and enables:In-depth,
More news about: RS
Jun 08, 2026, 09:06 ET GrubMarket Announces Sales AI Agent that Transforms Prospecting and Quote Creation for Food Distributors
with leading food distribution software solutions, including WholesaleWare ERP, Thyme Software, Granite State Software, PICS by WaudWare, and Orders IO. It is also available as a standalone solution with support for uploaded product catalogs and price groups.The Sales AI Agent streamlines
More news about: GrubMarket
Jun 02, 2026, 02:21 ET Movate and Leena AI Partner to Advance AI-Led Employee Experience
agents, it brings together human expertise and technology to help organizations rethink operating models for efficiency and growth. Powered by Mova iO, its intelligent outcomes platform, Movate delivers practical, scalable, and industry-contextualized solutions that address real business challenges.For
More news about: Movate
Jun 01, 2026, 07:00 ET Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration
targeting the ILT2–HLA-G axis. BND-22 has demonstrated efficacy in heavily treated cancer patients in indications that hardly respond to Immuno-Oncology (IO) therapies, such as MSS-CRC, and is currently being evaluated in an ongoing Phase 2 study at MD Anderson Cancer Center.BND-67 is Biond's next-generation
More news about: Biond Biologics Ltd.; GIBF
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
an ORR of 66.7% and a DCR of 100.0%. In the 30 mg/kg monotherapy cohort, patients whose disease had progressed following prior immunotherapy (IO) plus platinum-based chemotherapy —— a setting with significant unmet medical need—achieved an ORR of 30.8% and a DCR of 84.6%."Cold
More news about: CStone Pharmaceuticals